Patents by Inventor Stephan Kling

Stephan Kling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8993753
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: March 31, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Ostermeier, Juergen Daeubler, Guenther Huchler, Stephan Kling, Marco Santagostino
  • Publication number: 20140135495
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 15, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Markus OSTERMEIER, Juergen DAEUBLER, Guenther HUCHLER, Stephan KLING, Marco SANTAGOSTINO
  • Patent number: 8658790
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Ostermeier, Juergen Daeubler, Guenther Huchler, Stephan Kling, Marco Santagostino
  • Publication number: 20130196049
    Abstract: There is provided a process for preparing a reduced sodium salt composition, the process comprising the steps of mixing sodium chloride with one or more sodium chloride substitute complexes, heating the so-formed mixture to form a melt, and cooling the melt to form a solid. The so-formed solid is a fused granular matrix of sodium chloride and one or more sodium chloride substitute complexes. An alternative process is provided in which the sodium chloride and the sodium chloride substitute complex are heated to the liquid phase before they are combined. A reduced sodium salt composition is also provided, in particular a reduced sodium chloride salt obtained from these processes.
    Type: Application
    Filed: April 14, 2010
    Publication date: August 1, 2013
    Applicant: KLINGE CHEMICALS LTD.
    Inventors: Douglas Hugh Brown, Michael Klinge, Stephan Klinge
  • Publication number: 20110183987
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Application
    Filed: July 30, 2010
    Publication date: July 28, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Markus OSTERMEIER, Juergen DAEUBLER, Guenther HUCHLER, Stephan Kling, Marco SANTAGOSTINO